Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Stephanie Cherqui
With
California Institute for Regenerative Medicine (CIRM)
Cystinosis Research Foundation
Novartis Pharmaceuticals
Participants enrolled in a study where the individual received CTNS-RD-04 will be offered participation in the CTNS-RD-04-LTF01 study. The Baseline visit for the CTNS-RD-04-LTF01 study will likely coincide with the final visit in the parent study. Participants confirmed eligible for the CTNS-RD-04-LTF01 study will be asked to return for study visits at approximately 6-month intervals for the first 4 years and annually thereafter for up to 11 years until a total of 15 years have elapsed during which time continued safety, engraftment, and efficacy of CTNS-RD-04 treatment will be assessed.
Age
14–50
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participant must have received CTNS-RD-04 in a preceding study
You may not be if
Participant is currently enrolled in an CTNS-RD-04 treatment study. Participants who have either completed, withdrawn, or prematurely discontinued participation for any reason at any time after receiving CTNS-RD-04 are eligible for CTNS RD 04 LTF01 study participation.